BNTX:NASDAQ
BioNTech SE
US$Â 96.46
arrow_upward
+0.76%(+0.73) Siku 1
7 Okt, 12:58:25 GMT -4 · USD
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya BNTX...
Fungua
US$Â 95.17
Juu
US$Â 97.46
Chini
US$Â 93.92
Mtaji wa soko
24.23B
Wastani wa kiasi cha mauzo
1.01M
Kiasi cha mauzo ya hisa
elfu 346.90
Juu kwa wiki 52
US$Â 123.98
Chini kwa wiki 52
US$Â 79.52
EPS
-US$Â 7.55
Beta
1.22
Hisa za wawekezaji
251.20M
Idadi ya wafanyakazi
elfu 8
Fungua
US$Â 95.17
Juu
US$Â 97.46
Chini
US$Â 93.92
Mtaji wa soko
24.23B
Wastani wa kiasi cha mauzo
1.01M
Kiasi cha mauzo ya hisa
elfu 346.90
Juu kwa wiki 52
US$Â 123.98
Chini kwa wiki 52
US$Â 79.52
EPS
-US$Â 7.55
Beta
1.22
Hisa za wawekezaji
251.20M
Idadi ya wafanyakazi
elfu 8
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
GuruFocus
·
saa 1 iliyopita
BNTX Maintained by Morgan Stanley -- Price Target Lowered to $11
Investing.com Nigeria
·
saa 12 zilizopita
Form 4 BioNTech SE For: 7 October By Investing.com
AD HOC NEWS
·
saa 18 zilizopita
BioNTech stock fell 1.96 percent despite a Buy consensus
Yahoo Finance
·
siku 1 iliyopita
Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips
Wasifu
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Kuhusu BioNTech SE